Spolupráca stavia na poprednej platforme spoločnosti Neomorph zameranej na objav molekulárneho lepidla a rozsiahlych odborných znalostiach spoločnosti Novo Nordisk v oblasti kardiometabolických a ...

Neomorph, Inc. announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and commercialize molecular glue degraders.

La colaboración aprovecha la plataforma líder de descubrimiento de pegamentos moleculares de Neomorph y la amplia experiencia de Novo Nordisk en enfermedades cardiometabólicas y raras. Valor potencial ...

The partnership will leverage Neomorph’s molecular glue discovery platform. Credit: PeopleImages.com – Yuri A/Shutterstock. Biogen and Neomorph have entered a research partnership aimed at discovering ...

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company advancing a new class of molecular glue degraders to target historically undruggable proteins, today announced the ...

Neomorph, Inc. announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs. Deerfield Management Company established Neomorph ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Neomorph, Inc. today announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and ...

SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE)-- Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the closing of a ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible ...